Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Restructuring watch

Restructuring watch

Date Company Staff cuts Current cash Cash date Operating loss Op loss period
6/19 CuraGen (CRGN) 20% to 320 $395.0 3/31 $17.5 1Q ended 3/31
The company's second restructuring will

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE